A transdisciplinary forum for study of individual and population variability in response to health interventions and personalized medicine

Current Pharmacogenomics and Personalized Medicine

Volumn 7, Issue 3, 2009, Pages 146-148

  Ozdemir, V ^a   Someya, T ^b  

^a NIIGATA UNIVERSITY   (Japan)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CANNABIDIOL; TRANSCRIPTOME;

DIABETIC RETINOPATHY; EDITORIAL; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HUMAN; INTERVENTION STUDY; MENTAL DISEASE; NUTRIGENOMICS; PHARMACOGENETICS; PHARMACOGENOMICS; PUBLIC HEALTH PROBLEM; PUBLICATION;

EID: 72449149697     PISSN: 18756921     EISSN: 18756913     Source Type: Journal    
DOI: 10.2174/1875692110907030146     Document Type: Editorial

References (25)

1. Sheiner LB. Learning versus confirming in clinical drug development. Clin Pharmacol Ther 1997; 61(3): 275-291 (Pubitemid 27145429)
2. Reidenberg MM. Evolving ways that drug therapy is individualized. Clin Pharmacol Ther 2003; 74: 197-202.
3. Kalow W, Ozdemir V, Tang BK, et al. The science of pharmacological variability: an essay. Clin Pharmacol Ther 1999; 66(5): 445-447
4. Cohen N. Pharmacogenomics and Personalized Medicine. Totowa, NJ: Humana Press 2008.
5. McNally R, Glasner P. Survival of the gene? 21st century visions from genomics, proteomics and the new biology. In: Glasner P, Atkinson P, Greenslade H, Eds. New Genetics, New Social Formations. London: Routledge 2007; pp. 253-278
6. Ozdemir V, Suarez-Kurtz G, Stenne R, et al. Risk assessment and communication tools for genotype associations with multifactorial phenotypes: the concept of "edge effect" and cultivating an ethical bridge between omics innovations and society. OMICS: A Journal of Integrative Biology 2009; 13(1): 43-61.
7. Poland GA. Pharmacology, vaccinomics, and the second golden age of vaccinology. Clin Pharmacol Ther 2007; 82(6): 623-626
8. Darnton-Hill I, Margetts B, Deckelbaum R. Public health nutrition and genetics: implications for nutrition policy and promotion. Proc Nutr Soc 2004; 63(1): 173-185 (Pubitemid 38543886)
9. Kaput J, Perlina A, Hatipoglu B, et al. Nutrigenomics: concepts and applications to pharmacogenomics and clinical medicine. Pharmacogenomics 2007; 8(4): 369-390 (Pubitemid 46591098)
10. Caudill MA, Dellschaft N, Solis C, et al. Choline intake, plasma riboflavin, and the phosphatidylethanolamine N-methyltransferase G5465A genotype predict plasma homocysteine in folate-deplete Mexican-American men with the methylenetetrahydrofolate reductase 677TT genotype. J Nutr 2009; 139(4): 727-733
11. Robitaille J. Nutrigenomics and personalized diet: what are the anticipated Impacts for research on chronic diseases and public health? Curr Pharmacogenomics Person Med 2009; 7(2): 106-114
12. Ferguson LR. Epigenetic variation and customising nutritional intervention. Curr Pharmacogenomics Person Med 2009; 7(2): 115-124
13. Eichelbaum M, Spannbrucker N, Dengler HJ. N-oxidation of sparteine in man and its interindividual differences. Arch Pharmacol 1975; 287: R94.
14. Mahgoub A, Idle JR, Dring LG, et al. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; 2: 584-586
15. Nebert DW, Zhang G, Vesell ES. From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. Drug Metab Rev 2008; 40: 187-224. (Pubitemid 352000946)
16. Little J, Higgins JP, Ioannidis JP, et al. STrengthening the REporting of Genetic Association Studies (STREGA): an extension of the STROBE statement. PLoS Med 2009; 6(2): e22.
17. Guessous I, Gwinn M, Yu W, et al. Trends in pharmacogenomic epidemiology: 2001-2007. Public Health Genomics 2009; 12(3): 142-148
18. Llerena A, Michel G, Jeannesson E, et al. Third Santorini conference pharmacogenomics workshop report: Pharmacogenomics at the crossroads: what else than good science will be needed for the field to become part of Personalized Medicine? Clin Chem Lab Med 2007; 45(7): 843-850
19. Woodcock J. Chutes and ladders on the critical path: Comparative effectiveness, product value, and the use of biomarkers in drug development. Clin Pharmacol Ther 2009; 86: 12-14
20. Quick JD. Ensuring access to essential medicines in the developing countries: a framework for action. Clin Pharmacol Ther 2003; 73: 279-283 (Pubitemid 36403587)
21. Hogerzeil HV. Essential medicines and human rights: what can they learn from each other? Bull World Health Organ 2006; 84(5): 371-375
22. Javitt G, Katsanis S, Scott J, et al. Developing the blueprint for a genetic testing registry. Public Health Genomics 2009 Jun 29 [Epub ahead of print].
23. Ozdemir V. Science policy and knowledge translation in the post-genomics era: A proposal for an 'Essential Diagnostics Library'. In: Symposium: Bridging the Continents in Istanbul: Personalized & Predictive Medicine in Turkey - Too Soon or Just-in-Time? Yeditepe University, Istanbul, September 2009 (in press).
24. David P, Foray D. Assessing and expanding the science and technology knowledge base. STI Review 1995; 16: 13-68.
25. Gardner H. Five Minds for the Future. Boston, MA: McGraw-Hill Ryerson Agency 2007.